Something New Every Day

Aronson, Jeffrey K

doi:10.1097/01.jac.0000304100.38120.b2

Cited by 21 publications

(3 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug innovation can take different aspects [ 8 ]. A first distinction should be made between an innovation implying a new substance and one that is a reformulation of an already existing drug.…”

Section: Introductionmentioning

confidence: 99%

Determinants of new drugs prescription in the Swiss healthcare market

Decollogny

Piaget-Rossel

Taffé

et al. 2018

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundDrug markets are very complex and, while many new drugs are registered each year, little is known about what drives the prescription of these new drugs. This study attempts to lift the veil from this important subject by analyzing simultaneously the impact of several variables on the prescription of novelty.MethodsData provided by four Swiss sickness funds were analyzed. These data included information about more than 470,000 insured, notably their drug intake. Outcome variable that captured novelty was the age of the drug prescribed. The overall variance in novelty was partitioned across five levels (substitutable drug market, patient, physician, region, and prescription) and the influence of several variables measured at each of these levels was assessed using a non-hierarchical multilevel model estimated by Bayesian Markov Chain Monte Carlo methods.ResultsMore than 92% of the variation in novelty was explained at the substitutable drug market-level and at the prescription-level. Newer drugs were prescribed in markets that were costlier, less concentrated, included more insured, provided more drugs and included more active substances. Over-the-counter drugs were on average 12.5 years older while generic drugs were more than 15 years older than non-generics. Regional disparities in terms of age of prescribed drugs could reach 2.8 years.ConclusionsRegulation of the demand has low impact, with little variation explained at the patient-level and physician-level. In contrary, the market structure (e.g. end of patent with generic apparition, concurrence among producers) had a strong contribution to the variation of drugs ages.

show abstract

Section: Introductionmentioning

confidence: 99%

Determinants of new drugs prescription in the Swiss healthcare market

Decollogny

Piaget-Rossel

Taffé

et al. 2018

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…On the principle that one should practise what you preach, I have previously published definitions, in collaboration with colleagues, based on some or all of the principles outlined here. The topics covered have included: adherence to medications23; adverse drug reactions and related terms24; artificial intelligence25; bias26; biomarkers27; complex systematic reviews28; drug shortages29; medical devices30; medication errors3132; me-too pharmaceutical products33; nutraceuticals34; pharmacological mechanisms35; the Precautionary Principle36; rapid reviews37; research and translational research3839; rewardable innovation and innovativeness in drug therapy4041; signals in pharmacovigilance42; surveillance of the effects of drug therapy43; unlicensed and off-label uses of medicines 44…”

Section: Definition In Practicementioning

confidence: 99%

When I use a word . . . .Devising bioscience definitions

Aronson

2023

BMJ

View full text Add to dashboard Cite

When I use a word . . . .Devising bioscience definitions Lexicographers' jobs include crafting definitions of words, a task that is not as easy as many think it is. To do this, one can call on four methods, alone or more often in combination, based on etymology, usages, previous definitions, and the Ramsay-Lewis method, in which a term or group of terms appearing in a theory can be defined implicitly by the assertions of the theory itself. Terms that I have defined using some or all of these methods include adherence to medications; adverse drug reactions and related terms; artificial intelligence; bias; biomarkers; complex systematic reviews; drug shortages; medical devices; medication errors; me-too pharmaceutical products; nutraceuticals; pharmacological mechanisms; the Precautionary Principle; rapid reviews; research and translational research; rewardable innovation and innovativeness in drug therapy; signals in pharmacovigilance; surveillance of the effects of drug therapy; unlicensed and off-label uses of medicines. Some of these definitions have been adopted internationally.

show abstract

“…Innovation in medications may arise from modifications to one or more of the properties of the compound, including the chemical structure or synthesis method of the drug; the pharmaceutical form; the pharmacodynamics; the pharmacokinetics; and other therapeutic properties (Aronson, 2008). The evaluation of innovation in the pharmaceutical industry has been widely debated, involving multiple perspectives covering the patients, the industry, the government and regulatory agencies, among other actors.…”

Section: Pharmaceutical Innovationmentioning

confidence: 99%

Inovação tecnológica na indústria farmacêutica: diferenças entre a Europa, os EUA e os países farmaemergentes

et al. 2016

View full text Add to dashboard Cite

Resumo Historicamente, o cenário farmacêutico mundial tem sido dominado por grandes multinacionais (Big Pharma), majoritariamente de origem europeia e norte-americana. Contudo, é consenso na literatura a importância crescente dos mercados farmacêuticos emergentes (países farmaemergentes), especialmente China e Brasil, que são vistos como os maiores responsáveis pelo crescimento sustentável do segmento farmacêutico. Esse artigo teve como objetivo realizar um mapeamento tecnológico e industrial do setor farmacêutico, a partir de informações de bancos de dados patentários internacionais (WIPO e Derwent), entre 1996 até o último ano de registro (2013). Utilizando-se o Método dos Mínimos Quadrados e implementação de um algoritmo no MATLAB, desenvolveram-se previsões para o período 2014-2018. Os resultados obtidos atestaram a liderança da Europa e dos EUA no setor, destacando-se o índice de inovação da Hoffmann-La Roche; a participação expressiva da China; e a pouca contribuição do Brasil no âmbito mundial. Todavia, estimou-se uma tendência de crescimento acentuado no número de proteções concedidas ao Brasil (41%) e à China (27%), apontando um alcance, até 2036, dos índices de patenteamento chineses aos números dos atuais líderes mundiais, trazendo a esperança da difusão tecnológica e científica e do aumento da competitividade no segmento farmacêutico.

show abstract

Something New Every Day

Cited by 21 publications

References 6 publications

Determinants of new drugs prescription in the Swiss healthcare market

Determinants of new drugs prescription in the Swiss healthcare market

When I use a word . . . .Devising bioscience definitions

Inovação tecnológica na indústria farmacêutica: diferenças entre a Europa, os EUA e os países farmaemergentes

Contact Info

Product

Resources

About